Browsing by Author "Eissa, Amal A. M"

Now showing 1 - 2 of 2

Novel coumarin-pyrazoline hybrids: synthesis, cytotoxicity evaluation and molecular dynamics study
(ROYAL SOC CHEMISTRY, THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND, 2021-09) Ragab, Fatma A; Eissa, Amal A. M; Fahim, Samar H; Salem, Mohammad Alaraby; Gamal, Mona A; Nissan, Yassin M
A novel series of coumarin-pyrazoline hybrids 3a-f, 4a-c and 5a-c have been synthesized and tested for their antiproliferative activity against the breast cancer cell line MCF-7. The most active compounds 3d, 3e, 3f, 5a and 5c were also evaluated for their ability to inhibit EGFR expression with reference to erlotinib. In silico studies using rigid docking, flexible docking and molecular dynamics were performed to explore the possibility of direct interactions between the active molecules and the ATP-binding site of EGFR. Most compounds demonstrated a potent cytotoxic activity against the MCF-7 cell line. The most active compounds 3d, 3e, 3f, 5a and 5c with IC50 values of 5, 26, 44, 20, and 50 nM, respectively, were further tested against HCT-116, HepG-2, A549 and SGC-7901 cell lines. All the tested compounds showed better activity than the reference standard drugs (doxorubicin and erlotinib) in all the tested cell lines. Compound 5a was the most potent one against HCT-116 with an IC50 value of 5 nM, while compound 3d was the most potent one against the breast cancer cell line MCF-7, liver HepG-2, lung A549 and the gastric cancer cell line SGC-7901 with IC50 values of 5, 77, 27 and 60 nM, respectively. Compounds 3d and 5a were tested for their cytotoxic effects on the normal breast cancer cell line MCF10a and their IC50 values were 35.78 and 22.77 mu M, respectively, indicating good selectivity. The most active compounds 3d, 3e, 3f, 5a and 5c exhibited percent reduction in EGFR level ranging from 80.9 to 88.0%. The apoptotic effect of compounds 3d and 5a on MCF-7 cells was investigated through cell cycle analysis. Both compounds showed increases in the number of cells in the pre-G1 phase of 14 and 22 folds, respectively, compared to the control. Both compounds exhibited total apoptosis of 28.06 and 43.88%, respectively. Docking of the new ligands revealed high scores compared to that of erlotinib. In the case of thiourea derivatives 3d and 3e, more stable hydrogen bonds via the thiourea group were demonstrated through molecular dynamics.
Synthesis and biological evaluation of new coumarin derivatives as cytotoxic agents
(wiley online library, 4/19/2021) Ragab, Fatma A; Eissa, Amal A. M; Fahim, Samar H; Salem, Mohammad A; Gamal, Mona A; Nissan, Yassin M
New coumarin derivatives 9a–f, 10a–e, and 11a–f were synthesized and evaluated for their cytotoxic activity against a human breast cancer cell line (MCF-7). All compounds exhibited good activity in the nanomolar range, using doxorubicin and erlotinib as positive controls. The most active compound 9d with IC50 of 21 nM was tested against the HCT-116, HepG-2, A549, and SGC-7901 cell lines, with IC50 values of 0.021, 0.170, 0.028, and 0.11 µM, respectively. Compound 9d was further investigated for its ability to suppress the expression of epidermal growth factor receptor (EGFR). Compound 9d decreased the concentration of EGFR by 87%, using erlotinib as a positive control. A docking study revealed similar or higher scores than for erlotinib and similar binding poses providing interactions with the hinge region of the tyrosine kinase (TK). Besides the effect on expression, this in silico investigation predicts the possibility of direct binding between the new coumarin derivatives and the EGFR TK. Moreover, computational calculation for ADME properties for the most active compounds 9d, 9e, 10c, and 11c revealed the expected high gastrointestinal tract absorption, moderate water solubility with no central nervous system toxicity, and druglikeness. © 2021 Deutsche Pharmazeutische Gesellschaft